How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drospirenone-ethinylestradiol-methyltetrahydrofolate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Drospirenone/Ethinylestradiol/Methyltetrahydrofolate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drospirenone/Ethinylestradiol/Methyltetrahydrofolate (Drospirenone/Ethinylestradiol/Methyltetrahydrofolate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive with folate supplementation. Area: Contraception / Women's Health.

phase 3 Oral contraceptive with folate supplementation Progesterone receptor, estrogen receptor Contraception / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Drospirenone/Ethinylestradiol/Methyltetrahydrofolate (Drospirenone/Ethinylestradiol/Methyltetrahydrofolate) — Bayer. This combination oral contraceptive prevents pregnancy by suppressing ovulation through progestin and estrogen activity, while methyltetrahydrofolate supplementation reduces neural tube defect risk.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate TARGET	Drospirenone/Ethinylestradiol/Methyltetrahydrofolate	Bayer	phase 3	Oral contraceptive with folate supplementation	Progesterone receptor, estrogen receptor
Drospirenone / Estetrol	Drospirenone / Estetrol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Female Contraceptive	Female Contraceptive	Italfarmaco	marketed	Hormonal contraceptive	Progesterone receptor, estrogen receptor
Drospirenone and Ethinyl Estradiol tablets	Drospirenone and Ethinyl Estradiol tablets	Hansoh BioMedical R&D Company	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Ortho Tri Cyclen	Ortho Tri Cyclen	Virginia Commonwealth University	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
YAZ®	YAZ®	Teva Pharmaceuticals USA	marketed	Oral contraceptive (combined estrogen-progestin)	Progesterone receptor, estrogen receptor, mineralocorticoid receptor
Kariva®	Kariva®	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive with folate supplementation class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Drospirenone/Ethinylestradiol/Methyltetrahydrofolate — Competitive Intelligence Brief. https://druglandscape.com/ci/drospirenone-ethinylestradiol-methyltetrahydrofolate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab